Abstract
In the repair of structural tissue, such as bone, the bridging of gaps between tissue boundaries and the spatial resolution of defect sites are frequent challenges. In the repair of bone, bone ends must be stabilized and bone stability must be maintained during healing. The goals in repair of bone tissue are complete restoration of function and aesthetic acceptability. Two lines of current orthopedic research address these problems. The first deals with biomaterials development where biodegradable bone cements are sought to replace excised bone fragments and, with erosion rates commensurate with growth of new bone, serve as osteoconductive pathways for healing. The second deals with utilization of bone repair proteins (BRPs) where bone growth is actively promoted and the BRPs function as osteoinductive materials. The former addresses bone stabilization, the latter the duration of the healing processes. Although bone morphogen(et)ic protein (BMP) and osteogenic protein (OP) are more commonly used terms in reference to the bone repair proteins, these terms and their initials are increasingly associated with particular company products. We will use BRP to discuss the more general field of repair proteins, and reserve “BMP” or “OP” for specific product references.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Urist MR. Bone: formation by autoinduction, Science 1965; 150: 893.
Takahashi S, Iwata H, and Hanamura H. Nature of bone morphogenetic protein from decalcified rabbit bone matrix. Nippon Seikeigeka Gakkai Zasshi 1987; 61 (2): 197–204.
Urist MR, Chang JJ, Lietze A, Huo YK, Brownell AG, and DeLange RJ. Preparation and bioassay of bone morphogenetic protein and polypeptide fragments. Methods Enzymol 1987; 146: 294–312.
Moore TM, Artal R, Arenas M, and Gendler E. Influence of postmortem time and temperature on osteoinductive activity of ethylene oxide sterilized syngenetic bone implant in the rat. Clin Orthop 1990; (259): 239–244.
Hattori T. Experimental investigations of osteogenesis and chondrogenesis by implant of BMPfibrin glue mixture. Nippon Seikeigekka Gakkai Zasshi 1990; 64: (9): 824–834.
Bessho K, Tagawa T, and Murata M. Purification of bone morphogenetic protein derived from bovine bone matrix. Biochem Biophys Res Commun 1989; 165 (2): 595–601.
Paralkar VM, Nandedkar AK, Pointer RH, Kleinman HK, and Reddi AH. Interaction of osteogenin, a heparin binding bone morphogenetic protein with type IV collagen. J Biol Chem 1990; 5:265(28): 17,281–17,284.
Meiki A, Kawai T, Ishegure K, Mizutani M, Hasegawa J, and Umemura M. Bone inductive activity of bone morphogenetic protein combined to beta tricalcium phosphate. Shika Zairyokikai 1989; 8 (2): 224–230.
Johnson EE, Urist MR, and Finnerman GA. Distal metaphyseal nonunion. Deformity and bone loss treated by open reduction, internal fixation, and human bone morphogenetic protein (hBMP). Clin Orthop 1990; 250: 234–240.
Hollinger JO, Schmitz JP, Mark DE, and Syfer AE. Osseous wound healing with xenogenetic bone implants with a biodegradable carrier. Surgery 1990; 107 (1): 50–54.
Katthagen BD. Bone induction with bone morpho-genetic protein. Z Orthop 1987; 125 (5): 559–566.
Ferguson D, Davis WL, Urist MR, Hurt WC, and Allen EP. Bovine bone morphogenetic protein (bBMP) fraction-induced repair of craniotomy defects in the rhesus monkey (Macaca speciosa). Clin Orthop 1987; 219: 251–258.
Kawamura M, Iwata H, Sata K, and Miura T. Chondroosteogenetic response to crude bone matrix proteins bound to hydroxyapatite. Clin Orthop 1987; 217: 281–292.
Takaoka K, Nakahara H, Yoshikawa H, Masuhara K, Tsuda T, and Ono K. Ectopic bone induction on and in porous hydroxyapatite combined with collagen and bone morphogenetic protein. Clin Orthop 1988; 234: 250–254.
Urist MR, Nilsson O, Rasmussen J, Hirota W, Lovell T, Schmalzreid T, and Finerman GA. Bone regeneration under the influence of a bone morphogenetic protein (BMP) beta tricalcium phosphate (TCP) composite in skull trephine defects in dogs. Clin Orthop 1987; 214: 295–304.
Yamazaki Y, Oida S, Akimoto Y, and Shioda S. Response of mouse femoral muscle to an implant of a composite of bone morphogenetic protein and plaster of paris. Clin Orthop 1988; 234: 240–249.
Kawamura M and Urist MR. Growth factors, mitogens, cytokines, and bone morphogenetic proteins in induced chondrogenesis in tissue culture. Dey Biol 1988; 130 (2): 435–442.
Johnson EE, Urist MR, and Finerman GA. Repair of segmental defects of the tibia with cancellous bone grafts augmented with human bone morpho-genetic protein. A preliminary report. Clin Orthop 1988; 236: 249–257.
Lindholm TC, Lindholm TS, Alitalo I, and Urist MR. Bovine bone morphogenetic protein induced repair of skull trephine defects in sheep. Clin Orthop 1988; 277: 265–268.
Kawamura M and Urist MR. Induction of callus formation by implants of bone morphogenetic protein and associated bone matrix noncollagenous protein. Clin Orthop 1988; 236: 240–248.
Kawamura M and Urist MR Human fibrin is a physiologic delivery system for bone morphogenetic protein. Clin Orthop 1988; 235: 302–310.
Lovell TP, Dawson EG, Nilsson OS, and Urist MR. Augmentation of spinal fusion with bone morphogenetic protein in dogs. Clin Orthop 1989; 243: 266–274.
Wang EA, Rosen V, Cordes P, Hewick RM, Kriz MJ, Luxenberg DP, et al. Purification and characterization of other distinct bone inducing factors. Proc Natl Acad Sci USA 1988; 85 (24): 9484–9488.
Urist MR, HuoYK, Brownell AG, Holh WM, Buyske J, Leitze A, et al. Purification ofbovine bone morpho-genetic protein by hydroxyapatite chromatography. Proc Natl Acad Sci USA 1984; 81, 371–375.
Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, and Kriz RW. Novel regulators of bone formation: molecular clones and activities. Science 1988; 242 (4885): 1528–1534.
Wang EA, Rosen V, D’Allesandro JS, Bauduy M, Cordes P, Harada T, et al. Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci USA 1990; 87: 2220–2224.
Sampath TK and Reddi H. Dissociative extraction and reconstitution of extracellular matrix components involved in local bone differentiation. Proc Natl Acad Sci USA 1981; 78: 7599–7603.
Ozkaynak E, Rueger DC, Drier EA, Corbett C, Ridge R, Sampath TK, et al. OP-1 cDNA encodes an osteogenic protein in the TGF-ß family. Embro J 1990; 9: 2085–2093.
Sampath TK, Couglin JE, Whetstone RM, Banach D, Corbett C, Ozkaynak E, et al. Bovine osteogenic protein is composed of dimers of OP-1 and BMP2a, two members of the TGF-ß superfamily. JBiol Chem 1990; 265: 13, 198–13, 205.
Wozney JM, Rosen V, Celeste AJ, Mitsack LM, Whitters MJ, Kriz RW, Hewick RM, and Wang EA. Novel regulators of bone formation: molecular clones and activities. Science 1988; 242: 1528–1534.
Celeste Ai, Iannazzi JA, Taylor RC, Hewick RM, Rosen V, and Wang EA. Identification of transforming growth factor b family members present in bone-inductive protein purified from bovine bone. Proc Natl Acad Sci USA 1990; 87: 9843–9847.
Sampath TK, Maliakal JC, Hauschka PV, Jones WK, Sasah H, Tucker RF, et al. Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. JBiol Chem 1992; 267: 20, 352–20, 362.
Wang EA, Rosen V, D’Alessandro JS, Baudy M, Cordes P, Harada T, et al. Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci USA 1990; 87: 2220–2224.
Hammonds RG Jr, Schwall R, Dudley A, et al. Bone-inducing activity of mature BMP-2b produced from a hybrid BMP-2a/2b precursor. J Endocrinol 1991; 5: 149–155.
Massaque J. TGF-ß family of growth and differentiation factors. Cell 1987; 49: 437, 438.
Cook SD, Baffes GC, Wolfe MW, Sampath TK, and Reuger DC. Healing of large segmental defects with recombinant human osteogenic protein-1 (rhOP-1). JBone Joint Surg 1994; 75A: 827–837.
Rutherford RB, Sampath TK, Rueger DC, and Taylor TD. Use of bovine osteogenic protein to promote rapid osseointegration of endoseous dental implants. Int J Oral Maxillofac Implants 1992; 7: 297–301.
Rutherford RB, Wahle J, Tucker M, Rueger DC, and Charette M. Recombinant human osteogenic protein-1 induces reparative dentine formation in monkeys. Arch Oral Biol (1993), in preparation.
Reddi AH and Huggins CB. Biochemical sequences in the transformation of normal fibroblasts in ado-lescent rats. Proc Natl Acad Sci USA 1972; 69: 1601–1605.
Bolander ME and Balian G. The use of demineralized bone matrix in the repair of segmental defects. JBone Joint Surg 1986; 68-A (8): 1264–1274.
Szmerczanyi IV, Marcos LK, Greger K, and MakayBodi E. Investigation of maleate-fumarate isomerization during esterification with various glycols. J Polymer Sci 1961; 53: 241–248.
Andreis M, Meic Z, and Veksli Z. Polymer 1983; 24: 661.
Andreis M, Veksli Z, and Meic Z. Polymer 1986; 26: 1099.
U.S. Patent no. 3,978,203 Aug 31, 1976.
Wise DL (ed). Polyesters from Krebs cycle monomers as vehicles for sustained release, in Biopolymeric Controlled Release Systems, vol 2, Ch. 12, 1984; CRC, Boca Raton, FL.
Wise DL. Report to US Army Institute of Dental Research. (Dynatech R/D Co.) Contract No. DAMD 17–80-C-0186.
Wise DL, Wentworth RL, Sanderson JE, and Crooker SC. Evaluation of repair materials for avulsive combat-type maxillofacial injuries, in Biopolymeric Controlled Release Systems, vol 2, Ch. 11, 1984; ( Wise DL, ed), CRC, Boca Raton, FL.
US Patent no. 4,722,948 Feb. 2, 1988.
IbayAC. Synthesis of a moldable biodegradable bone repair material, in Characterization and In Vivo Evaluation of Crosslinked Poly(Propylene) Fuma-rate 1987; Report to US Army Institute of Dental Research. Walter Reed Army Medical Center.
Domb AJ, Laurencin CT, Israeli O, Gerhart TN, and Langer R. JPolymer Sci A 1990; 28 (5): 973–985.
US Patent no. 4,888,413 Dec. 19, 1989.
Gerhart TN, Roux RD, Horowitz G, Miller RL, HanffP, and Hayes WC. Antibiotic release from an experimental biodegradable bone cement. JOrthopedic Res 1988; 6: 585–592.
Witschger PM, Gerhart TN, Goldman JB, Edsberg LE, and Hayes WC. Biomechanical evaluation of a biodegradable composite as an adjunct to internal fixation of proximal femur fractures. J Orthopedic Res 1991; 9: 48–53.
DuChamp JG. In vitro release of isoniazid from dry mixed extruded matrices. Masters thesis, Northeastern University, 1992.
Cutright DE, Perez B, Beasley JD, Larson WJ, and Posey WR. Degradation rates of polymers and copolymers of polylactic and polyglycolic acids. Oral Surg Oral Med Oral Pathol 1974; 37: 142–152.
Wise DL (ed). Biopolymeric Controlled Release Systems,vol 1, 1984; Ch 2, CRC, Boca Raton, FL.
The Merck Index,11th ed, 1989; (Budavar S, ed), Merck and Co., Inc., Rahway, NJ, p 699.
Polymer Handbook,3rd ed, 1989; (Brandrup J and Inerut EH, eds), Wiley, New York, pp 11–183.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Wise, D.L. et al. (1996). Bone Cement, Part 2. In: Wise, D.L., Trantolo, D.J., Altobelli, D.E., Yaszemski, M.J., Gresser, J.D. (eds) Human Biomaterials Applications. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-4757-2487-5_9
Download citation
DOI: https://doi.org/10.1007/978-1-4757-2487-5_9
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-012-0
Online ISBN: 978-1-4757-2487-5
eBook Packages: Springer Book Archive